Global Tianeptine 麻豆原创 Research Report 2024

Publication ID:

PB506244556

Publication Date:

June 20, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Tianeptine, sold under the brand names Stablon and Coaxil among others, is an atypical antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.
The global Tianeptine market was valued at US$ 2247 million in 2023 and is anticipated to reach US$ 3070.1 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Tianeptine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tianeptine.
Report Scope
The Tianeptine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Tianeptine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tianeptine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Servier
Lupin Limited
PharmaS
Antibiotice
Serdia Pharmaceuticals
Alvogen
Bausch Health
Genefar B.V.
Arena Pharmaceuticals
Glenmark
Novartis
Dongwha Pharm
Liconsa SA
Mylan
Adamed
Neuraxpharm Arzneimittel
Grupo Insud
Segment by Type
Patent
Generic
Segment by Application
Depression and Anxiety
Irritable Bowel Syndrome
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tianeptine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Tianeptine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Tianeptine 麻豆原创 Overview
1.1 Product Overview and Scope of Tianeptine
1.2 Tianeptine Segment by Type
1.2.1 Global Tianeptine 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Patent
1.2.3 Generic
1.3 Tianeptine Segment by Application
1.3.1 Global Tianeptine 麻豆原创 Value by Application: (2024-2030)
1.3.2 Depression and Anxiety
1.3.3 Irritable Bowel Syndrome
1.4 Global Tianeptine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Tianeptine Revenue 2019-2030
1.4.2 Global Tianeptine Sales 2019-2030
1.4.3 Global Tianeptine 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Tianeptine 麻豆原创 Competition by Manufacturers
2.1 Global Tianeptine Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Tianeptine Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Tianeptine Average Price by Manufacturers (2019-2024)
2.4 Global Tianeptine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Tianeptine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Tianeptine, Product Type & Application
2.7 Tianeptine 麻豆原创 Competitive Situation and Trends
2.7.1 Tianeptine 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Tianeptine Players 麻豆原创 Share by Revenue
2.7.3 Global Tianeptine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Tianeptine Retrospective 麻豆原创 Scenario by Region
3.1 Global Tianeptine 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Tianeptine Global Tianeptine Sales by Region: 2019-2030
3.2.1 Global Tianeptine Sales by Region: 2019-2024
3.2.2 Global Tianeptine Sales by Region: 2025-2030
3.3 Global Tianeptine Global Tianeptine Revenue by Region: 2019-2030
3.3.1 Global Tianeptine Revenue by Region: 2019-2024
3.3.2 Global Tianeptine Revenue by Region: 2025-2030
3.4 North America Tianeptine 麻豆原创 Facts & Figures by Country
3.4.1 North America Tianeptine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Tianeptine Sales by Country (2019-2030)
3.4.3 North America Tianeptine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Tianeptine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Tianeptine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Tianeptine Sales by Country (2019-2030)
3.5.3 Europe Tianeptine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Tianeptine 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Tianeptine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Tianeptine Sales by Country (2019-2030)
3.6.3 Asia Pacific Tianeptine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Tianeptine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Tianeptine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Tianeptine Sales by Country (2019-2030)
3.7.3 Latin America Tianeptine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Tianeptine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Tianeptine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Tianeptine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Tianeptine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Tianeptine Sales by Type (2019-2030)
4.1.1 Global Tianeptine Sales by Type (2019-2024)
4.1.2 Global Tianeptine Sales by Type (2025-2030)
4.1.3 Global Tianeptine Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Tianeptine Revenue by Type (2019-2030)
4.2.1 Global Tianeptine Revenue by Type (2019-2024)
4.2.2 Global Tianeptine Revenue by Type (2025-2030)
4.2.3 Global Tianeptine Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Tianeptine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Tianeptine Sales by Application (2019-2030)
5.1.1 Global Tianeptine Sales by Application (2019-2024)
5.1.2 Global Tianeptine Sales by Application (2025-2030)
5.1.3 Global Tianeptine Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Tianeptine Revenue by Application (2019-2030)
5.2.1 Global Tianeptine Revenue by Application (2019-2024)
5.2.2 Global Tianeptine Revenue by Application (2025-2030)
5.2.3 Global Tianeptine Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Tianeptine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Servier
6.1.1 Servier Corporation Information
6.1.2 Servier Description and Business Overview
6.1.3 Servier Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Servier Tianeptine Product Portfolio
6.1.5 Servier Recent Developments/Updates
6.2 Lupin Limited
6.2.1 Lupin Limited Corporation Information
6.2.2 Lupin Limited Description and Business Overview
6.2.3 Lupin Limited Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Lupin Limited Tianeptine Product Portfolio
6.2.5 Lupin Limited Recent Developments/Updates
6.3 PharmaS
6.3.1 PharmaS Corporation Information
6.3.2 PharmaS Description and Business Overview
6.3.3 PharmaS Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 PharmaS Tianeptine Product Portfolio
6.3.5 PharmaS Recent Developments/Updates
6.4 Antibiotice
6.4.1 Antibiotice Corporation Information
6.4.2 Antibiotice Description and Business Overview
6.4.3 Antibiotice Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Antibiotice Tianeptine Product Portfolio
6.4.5 Antibiotice Recent Developments/Updates
6.5 Serdia Pharmaceuticals
6.5.1 Serdia Pharmaceuticals Corporation Information
6.5.2 Serdia Pharmaceuticals Description and Business Overview
6.5.3 Serdia Pharmaceuticals Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Serdia Pharmaceuticals Tianeptine Product Portfolio
6.5.5 Serdia Pharmaceuticals Recent Developments/Updates
6.6 Alvogen
6.6.1 Alvogen Corporation Information
6.6.2 Alvogen Description and Business Overview
6.6.3 Alvogen Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Alvogen Tianeptine Product Portfolio
6.6.5 Alvogen Recent Developments/Updates
6.7 Bausch Health
6.6.1 Bausch Health Corporation Information
6.6.2 Bausch Health Description and Business Overview
6.6.3 Bausch Health Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bausch Health Tianeptine Product Portfolio
6.7.5 Bausch Health Recent Developments/Updates
6.8 Genefar B.V.
6.8.1 Genefar B.V. Corporation Information
6.8.2 Genefar B.V. Description and Business Overview
6.8.3 Genefar B.V. Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Genefar B.V. Tianeptine Product Portfolio
6.8.5 Genefar B.V. Recent Developments/Updates
6.9 Arena Pharmaceuticals
6.9.1 Arena Pharmaceuticals Corporation Information
6.9.2 Arena Pharmaceuticals Description and Business Overview
6.9.3 Arena Pharmaceuticals Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Arena Pharmaceuticals Tianeptine Product Portfolio
6.9.5 Arena Pharmaceuticals Recent Developments/Updates
6.10 Glenmark
6.10.1 Glenmark Corporation Information
6.10.2 Glenmark Description and Business Overview
6.10.3 Glenmark Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Glenmark Tianeptine Product Portfolio
6.10.5 Glenmark Recent Developments/Updates
6.11 Novartis
6.11.1 Novartis Corporation Information
6.11.2 Novartis Tianeptine Description and Business Overview
6.11.3 Novartis Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Novartis Tianeptine Product Portfolio
6.11.5 Novartis Recent Developments/Updates
6.12 Dongwha Pharm
6.12.1 Dongwha Pharm Corporation Information
6.12.2 Dongwha Pharm Tianeptine Description and Business Overview
6.12.3 Dongwha Pharm Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Dongwha Pharm Tianeptine Product Portfolio
6.12.5 Dongwha Pharm Recent Developments/Updates
6.13 Liconsa SA
6.13.1 Liconsa SA Corporation Information
6.13.2 Liconsa SA Tianeptine Description and Business Overview
6.13.3 Liconsa SA Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Liconsa SA Tianeptine Product Portfolio
6.13.5 Liconsa SA Recent Developments/Updates
6.14 Mylan
6.14.1 Mylan Corporation Information
6.14.2 Mylan Tianeptine Description and Business Overview
6.14.3 Mylan Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Mylan Tianeptine Product Portfolio
6.14.5 Mylan Recent Developments/Updates
6.15 Adamed
6.15.1 Adamed Corporation Information
6.15.2 Adamed Tianeptine Description and Business Overview
6.15.3 Adamed Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Adamed Tianeptine Product Portfolio
6.15.5 Adamed Recent Developments/Updates
6.16 Neuraxpharm Arzneimittel
6.16.1 Neuraxpharm Arzneimittel Corporation Information
6.16.2 Neuraxpharm Arzneimittel Tianeptine Description and Business Overview
6.16.3 Neuraxpharm Arzneimittel Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Neuraxpharm Arzneimittel Tianeptine Product Portfolio
6.16.5 Neuraxpharm Arzneimittel Recent Developments/Updates
6.17 Grupo Insud
6.17.1 Grupo Insud Corporation Information
6.17.2 Grupo Insud Tianeptine Description and Business Overview
6.17.3 Grupo Insud Tianeptine Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Grupo Insud Tianeptine Product Portfolio
6.17.5 Grupo Insud Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Tianeptine Industry Chain Analysis
7.2 Tianeptine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Tianeptine Production Mode & Process
7.4 Tianeptine Sales and 麻豆原创ing
7.4.1 Tianeptine Sales Channels
7.4.2 Tianeptine Distributors
7.5 Tianeptine Customers
8 Tianeptine 麻豆原创 Dynamics
8.1 Tianeptine Industry Trends
8.2 Tianeptine 麻豆原创 Drivers
8.3 Tianeptine 麻豆原创 Challenges
8.4 Tianeptine 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Servier
Lupin Limited
PharmaS
Antibiotice
Serdia Pharmaceuticals
Alvogen
Bausch Health
Genefar B.V.
Arena Pharmaceuticals
Glenmark
Novartis
Dongwha Pharm
Liconsa SA
Mylan
Adamed
Neuraxpharm Arzneimittel
Grupo Insud

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.